-- （第四段更新了安桥公司的回应。） 美国最高法院周三驳回了安桥公司（Enbridge，股票代码：ENB）提出的将一起旨在阻止该公司运营5号输油管道的诉讼从密歇根州法院移交至联邦法院的动议。 密歇根州总检察长于2019年6月在州法院提起诉讼，试图阻止安桥公司运营这条全长645英里（约1040公里）的输油管道。该管道从威斯康星州西北部延伸至密歇根州，最终进入加拿大。 “因此，上诉法院的裁决是正确的，即安桥公司的移交通知已过时效，此案必须发回密歇根州法院，”索尼娅·索托马约尔大法官在代表最高法院发表的意见书中表示。“上诉法院的判决予以维持。” “撇开程序性裁决不谈，事实仍然是，5号输油管道的安全完全由管道和危险材料安全管理局（PHMSA）监管，”安桥公司在发给的电子邮件声明中表示。 “PHMSA每年都会对5号线在麦基诺海峡的运营进行检查和审查，并一直认为该管道符合规定，没有发现任何需要关闭该管道的安全问题。”
Price: $51.95, Change: $+0.09, Percent Change: +0.18%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.